A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.

Trish Thorne-Nuzzo,Crystal Williams, Alice Catallini,June Clements,Shalini Singh, James Amberson, Kim Dickinson,Zoran Gatalica,Steffan N Ho,Isabell Loftin,Abigail McElhinny,Penny Towne

Journal of Thoracic Oncology（2017）

引用 44|浏览15

暂无评分

摘要

The ALK (D5F3) CDx assay is a stand-alone companion diagnostic test for identification of patients for treatment with crizotinib. This automated assay provides an effective option to accurately and rapidly identify patients with ALK-positive NSCLC. The simple binary scoring algorithm results in high reader-to-reader precision.

查看译文

关键词

Anaplastic lymphoma kinase,NSCLC,Companion diagnostic assay,ALK IHC,Targeted therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要